Pfizer Seizes Strategic Edge in Obesity Drug Race with $10 B Bid for Metsera
In a bold strategic move designed to reposition itself in the booming weight-loss therapeutics market, Pfizer Inc. has secured the acquisition of Metsera, Inc., outbidding its rival Novo Nordisk A/S in a contest that underscores how and why the pharmaceutical giant is shifting its growth playbook. The deal marks more than just an asset purchase—it…









